Connor, Clark & Lunn Investment Management (CC&L)
ADVM

Connor, Clark & Lunn Investment Management (CC&L)’s Adverum Biotechnologies ADVM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18,261
Closed -$85.3K – 1387
2024
Q4 		$85.3K Buy
18,261
+5,057
+38% +$34K ﹤0.01% 1365
2024
Q3 		$92.7K Buy
+13,204
New +$95.9K ﹤0.01% 1373
2023
Q3 		– Sell
-8,428
Closed -$134K – 1340
2023
Q2 		$134K Sell
8,428
-6,558
-44% -$69K ﹤0.01% 1231
2023
Q1 		$108K Sell
14,986
-5,063
-25% -$35.8K ﹤0.01% 1147
2022
Q4 		$116K Sell
20,049
-324
-2% -$2.46K ﹤0.01% 1099
2022
Q3 		$194K Buy
20,373
+8,622
+73% +$113K ﹤0.01% 997
2022
Q2 		$141K Sell
11,751
-18,521
-61% -$194K ﹤0.01% 963
2022
Q1 		$397K Sell
30,272
-3,602
-11% -$52.7K ﹤0.01% 823
2021
Q4 		$596K Sell
33,874
-2,967
-8% -$59.4K ﹤0.01% 769
2021
Q3 		$799K Buy
+36,841
New +$940K ﹤0.01% 682
2019
Q2 		– Sell
-7,203
Closed -$377K – 975
2019
Q1 		$377K Sell
7,203
-1,630
-18% -$65.9K ﹤0.01% 714
2018
Q4 		$278K Sell
8,833
-6,832
-44% -$278K ﹤0.01% 799
2018
Q3 		$948K Sell
15,665
-500
-3% -$28.1K 0.01% 574
2018
Q2 		$857K Sell
16,165
-1,010
-6% -$60.7K ﹤0.01% 644
2018
Q1 		$996K Sell
17,175
-2,380
-12% -$148K 0.01% 484
2017
Q4 		$684K Sell
19,555
-3,320
-15% -$109K ﹤0.01% 573
2017
Q3 		$835K Sell
22,875
-60
-0.3% -$1.67K 0.01% 556
2017
Q2 		$573K Hold
22,935
– – ﹤0.01% 579
2017
Q1 		$619K Sell
22,935
-100
-0.4% -$2.84K ﹤0.01% 588
2016
Q4 		$668K Sell
23,035
-3,190
-12% -$104K ﹤0.01% 551
2016
Q3 		$1.08M Sell
26,225
-4,020
-13% -$153K 0.01% 460
2016
Q2 		$956K Sell
30,245
-980
-3% -$44.3K 0.01% 473
2016
Q1 		$1.61M Buy
31,225
+390
+1% +$21.8K 0.01% 367
2015
Q4 		$2.94M Buy
30,835
+10,875
+54% +$955K 0.02% 279
2015
Q3 		$1.65M Buy
19,960
+18,160
+1,009% +$2.32M 0.01% 324
2015
Q2 		$292K Buy
+1,800
New +$607K ﹤0.01% 500

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ADVM Position: Q1 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Adverum Biotechnologies (ADVM) in Q1 2025, closing a stake of 18,261 shares — an estimated $85.3K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ADVM in Q2 2015 and held it in 26 quarters. The position peaked at $2.94M in Q4 2015. 70 funds tracked by Wall St. Rank hold ADVM as of Q1 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Adverum Biotechnologies position as of Q1 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 18,261 Adverum Biotechnologies shares in Q1 2025, an estimated $85.3K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Adverum Biotechnologies in Q2 2015 and held it in 26 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Adverum Biotechnologies position peaked at $2.94M in Q4 2015.
  • 70 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.